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Abstract 
Among neurogenerative diseases, amyotrophic lateral sclerosis (ALS) is a fatal illness characterized 
by a progressive motor neuron dysfunction in the motor cortex, brainstem and spinal cord. ALS is 
the most common form of motor neuron disease; yet, to date, the exact etiology of ALS remains 
unknown. In the present work, we have explored the possibility of fungal infection in cerebrospinal 
fluid (CSF) and in brain tissue from ALS patients. Fungal antigens, as well as DNA from several 
fungi, were detected in CSF from ALS patients. Additionally, examination of brain sections from 
the frontal cortex of ALS patients revealed the existence of immunopositive fungal antigens 
comprising punctate bodies in the cytoplasm of some neurons. Fungal DNA was also detected in 
brain tissue using PCR analysis, uncovering the presence of several fungal species. Finally, pro-
teomic analyses of brain tissue demonstrated the occurrence of several fungal peptides. Collec-
tively, our observations provide compelling evidence of fungal infection in the ALS patients ana-
lyzed, suggesting that this infection may play a part in the etiology of the disease or may constitute 
a risk factor for these patients. 
Key words: Amyotrophic lateral sclerosis; fungal infection; fungal PCR; brain histological analysis; proteomic 
analysis. 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a devas-
tating neurodegenerative disease that usually leads to 
death within 1-5 years period of diagnosis [1] ALS is a 
neuromuscular disease in which motor neurons lo-
cated in the brain or spinal cord degenerate, giving 
rise to muscular weakness and atrophy. This loss of 
motor neurons leads to fatal paralysis and death and 
is the most frequent disease of motor neurons [1]. The 
vast majority of ALS cases are sporadic (about 95%), 
whereas only a few are familial. In familial ALS, a 
number of mutations in several genes have been de-
scribed, including Cu/Zn-superoxide dismutase 
(SOD1) [2, 3]. Relationships between ALS and other 
neurodegenerative diseases have been noted, partic-
ularly with frontotemporal dementia (FTD) [4]. As 
occurs with most neurodegenerative diseases, the 
etiology of ALS remains unknown despite intensive 
research. The existence of aberrant protein aggregates 
inside neurons and glial cells constitutes an important 
hallmark for the classification of neurodegenerative 
diseases. In ALS, several proteins have been identified 
forming aggregates inside the cells in most patients. 
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This is exemplified by ubiquitinated inclusions, as 
well as detection of transactive response (TAR)-DNA 
binding protein 43 (TDP-43) and the fused in sarcoma 
protein (FUS) in cytoplasmic granules [5-7]. TDP-43 
exhibits a predominant nuclear localization, shuttling 
between the nucleus and cytoplasm, and is widely 
expressed in most cell types [8]. TDP-43 can interact 
with both DNA and RNA, and also with some mem-
bers of the heterogeneous nuclear ribonucleoprotein 
family, participating in the process of transcription 
and splicing [9, 10]. In this way, TDP-43 modulates a 
number of cellular functions including apoptosis [11]. 
FUS protein is also expressed in a wide array of cells, 
and shuttles between nucleus and cytoplasm with the 
capacity to interact with nucleic acids. FUS is involved 
in a number of cellular processes, including tran-
scription and RNA processing, cell proliferation and 
DNA repair [12]. Together with TDP-43 and FUS, a 
number of related proteins are under investigation as 
potential participants in ALS pathogenesis, including 
hnRNPA1, TAF15 and EWSR1 [6, 13-15].  
 The presence of cytoplasmic aggregates consti-
tutes the basis for classification of different subtypes 
of both ALS and FTD, and it has been suggested that 
different protein aggregates may govern pathological 
mechanisms [4]. However, it is still unclear what 
practical value this classification provides for diagno-
sis and for future potential therapies. The central 
concept of ALS research is that mutations in some 
genes may lead to the synthesis of aberrant proteins 
that are misfolded, giving rise to cytoplasmic aggre-
gates that are pathological for the correct functioning 
of motor neurons [16].  Accordingly, a number of 
mutations have been identified in TARDBP, the gene 
encoding TDP-43, and in the FUS gene [16]. These 
mutations only account for a small percentage of ALS 
cases; consequently, the number of candidate ALS 
genes is steadily increasing [16]. An intriguing ques-
tion in the field is why mutations in different genes 
manifest after many years in the patient´s lifetime and 
also why these protein inclusions are specifically 
pathological for motor neurons and are not present in 
other cell types.  
 Similarities exist between ALS and Alzheimer’s 
disease (AD), with regards to the presence of hyper-
phosphorylated tau protein in some neural cells and 
the formation of amyloid peptide [17, 18]. Recently, 
we have reported that fungal infection may play a 
part in the development of AD [19-21]. Fungal pro-
teins and polysaccharides are present in the blood of 
AD patients and, more significantly, fungal proteins 
and DNA can be detected in brain samples from AD 
patients. Further, direct visualization of intracellular 
fungal infection in neurons from the frontal cortex of 
AD patients could be demonstrated with fun-
gal-specific antibodies. Interestingly, chitin-like pol-
ysaccharides have been detected in AD brains and 
chitinase is elevated in cerebrospinal fluid (CSF) from 
AD patients [22-24]. To our knowledge, the possibility 
that a microbial infection could be the cause of ALS 
has thus far not been considered, although some cor-
relations has been found between sporadic ALS and 
enterovirus infections [25]. More recently, elevated 
chitinase levels have been detected in CSF from ALS 
patients [26, 27]. In the present work, we have evalu-
ated the existence of fungal proteins and DNA in CSF 
and brain samples from ALS patients. Our findings 
provide evidence for disseminated fungal infection in 
the central nervous system (CNS) in ALS patients. 
Materials and Methods 
Description of patients  
 The samples analyzed in this study correspond 
to cerebrospinal fluid (CSF) and tissue sections ob-
tained from brain donors diagnosed with ALS. Details 
about the age and gender of each patient are listed in 
Supplementary Tables SI and SII. All samples were 
supplied by Banco de Tejidos, Fundación CIEN (Cen-
tro de Investigación de Enfermedades Neurologicas). 
The Ethics Committee of Universidad Autónoma de 
Madrid approved the study. The transfer of samples 
was performed according to national regulations 
concerning research on human biological samples. For 
all cases, written informed consent is available. All 
ethico-legal documents of the brain bank, including 
written informed consent, have been approved by an 
ethics committee external to the bank. The data ob-
tained in this study was analyzed by an observer 
blinded to the diagnosis. 
Preparation of antifungal antibodies 
 Rabbit antisera against Candida famata, C. albi-
cans, C. parapsilosis, C. glabrata, and Penicillium notatum 
were obtained by inoculation of 1 or 2 mg of dried 
fungi (after autoclaving and lyophilization) in 0.5 ml 
PBS. Rabbit antiserum against peptide B tubulin-KLH 
(keyhole limpet hemocyanin) was purchased from 
PolyPeptide Group (Strasbourg, France). Each inocu-
lum had been previously mixed with an equal volume 
of Freund's adjuvant. Rabbits were inoculated up to 
three times every three weeks and the antibody titer 
and specificity of the sera were tested by immuno-
histochemistry and immunoblotting. For antiserum 
against recombinant enolase of C. famata, 
pMAL-enolase was cloned using 5´Eno and 3´Eno 
primers (CGCCGCGGATCCATGGCCGTCACTAA 
GTTATT and CGCCGCGTCGACTTATAATTGA 
GAAGCAGCGT, respectively) and expressed in E. coli 
BL21 for purification via Ni-NTA Superflow 
(Promega) chromatography. Purified protein was 
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then inoculated in rats, as described with rabbits. 
Slot-blot assay of fungal proteins  
To estimate the presence of fungal protein anti-
gens, CFS was diluted and filtered through nitrocel-
lulose membranes. A 200 µl volume of different CFS 
dilutions (1:10) in TBS was added to each well. Sam-
ples were blotted onto a 0.45-microns nitrocellulose 
membrane (Bio-Rad) previously hydrated in TBS for 
10 minutes, using the Bio-Dot SF apparatus (Bio-Rad). 
After blotting, the membrane was processed and de-
veloped as described [28, 29]. The primary antibodies, 
rabbit polyclonal antibodies raised against C. famata, 
C. albicans, C. parapsilosis, C. glabrata, P. notatum and 
peptide of beta tubulin KLH, were used at a 1:500 
dilution. A donkey anti-rabbit IgG horseradish pe-
roxidase-conjugated secondary antibody (Amersham 
Biosciences) was used at a 1:5000 dilution. Rat poly-
clonal antibody raised against C. famata enolase of was 
used at a 1:200 dilution. A rabbit anti-rat IgG horse-
radish peroxidase-conjugated secondary antibody 
(Sigma) was used at a 1:5000 dilution. Densitometric 
analysis of the film was carried out using a GS-800 
Calibrated Densitometer (Bio-Rad). The median of 
three different experiments and the cut-off of these 
values are indicated in the Results section. In previous 
studies, we established that values below 10 in this 
assay should be considered negative, between 10 and 
20 as uncertain, and values above 20 as positive. In the 
latter case, values between 20 and 50 are considered 
low, between 50 and 80 as moderate and above 80 as 
high. 
DNA Extraction from CSF 
To extract DNA from CSF samples we followed 
this procedure: 20 µl of proteinase K (>600mAU/ml) 
was added to 150 µl of CSF and 200 µl buffer AL 
(QIAmp Kit, Qiagen) and mixed for 15 s. 200 µl etha-
nol was added to each sample after incubation at 56ºC 
for 10 min, followed by mixing by pulse-vortexing for 
15 s. The mixture was then applied to the QIAamp 
Mini spin column and centrifuged at 8,000 rpm for 1 
min. Afterwords, 500 µl buffer AW was added and 
samples were centrifuged at 8,000 rpm for 1 min. 
Next, 500 µl buffer AW2 was applied, followed by 
centrifugation at 14,000 rpm for 3 min. Finally, each 
sample was suspended in 40 µl distilled water. DNA 
from extracts was quantified with a NanoDrop® 
ND-1000 UV-Vis Spectrophotometer. As negative 
controls we employed three samples of tri-distilled 
filtered water. 
DNA Extraction from tissue  
Brain samples were used to extract DNA using 
the QIAmp (Qiagen) genomic DNA isolation kit as 
follows: 20 µl proteinase K (>600mAU/ml) and 180 µl 
of buffer ATL were added to 25 mg of brain tissue, 
followed by pulse-vortexing for 15 s. Then, it was 
incubated at 56ºC for 1-3 h with agitation. A 200 µl 
volume of buffer AL was added to each sample fol-
lowed by vortexing for 15 s and incubation at 70ºC for 
10 min. 200 µl ethanol was added to each sample with 
vortexing for 15 s. The mixture was applied to the 
QIAamp Mini spin column and centrifuged at 8,000 
rpm for 1 min. After, 500 µl buffer AW was applied to 
the column, which was centrifuged at 8,000 rpm for 1 
min. 500 µl buffer AW2 was applied and the column 
was centrifuged at 14,000 rpm for 3 min. Finally, each 
sample was collected in 40 µl distilled water and 
quantification of DNA was carried out with a 
NanoDrop® ND-1000 UV-Vis Spectrophotometer 
and. negative controls three samples of tri-distilled 
filtered water were employed.  
Design of oligonucleotides  
ITS oligonucleotides. The gene sequences of 5.8S 
and 18S rRNA, as well as internal transcribed spacer 1 
(ITS 1) region from several organisms (C. albicans, C. 
famata, C. parapsilosis, C. glabrata, Rhodotorula muci-
laginosa, Pichia guilliermondii, Cryptococcus neoformans 
and Homo sapiens) were accessed via the GenBank da-
tabase and were aligned using the Clustal W sequence 
analysis package. Multiple potential primer-binding 
sites for this panfungal primer pair were chosen by 
comparing regions of Candida homologous with re-
gions of the fungal group within the fungal kingdom 
with the most divergent DNA sequences and regions 
of Candida incongruous with the human DNA se-
quence. The primer selection was optimized for 
melting temperature equivalence, lack of duplex, 
hairpin, or primer-dimer formation, and internal sta-
bility by using OLIGO software (Amplify).  
Nested PCR  
A number of measures were used to avoid PCR 
assay contamination. Thus, we used separate rooms 
and glassware supplies for PCR set-up and products, 
aliquoted reagents, positive-displacement pipettes, 
aerosol-resistant tips, and multiple negative controls. 
DNA samples obtained from CSF or brain tissue were 
analyzed by nested PCR using the ITS-1 primers. The 
first PCR was carried out with 4 μl of DNA incubated 
at 95°C for 10 min and amplified with 30 cycles of 45 s 
at 94°C, 1 min at 57.3°C, and 45 s at 72°C. The oligo-
nucleotides used were forward 14485´ 
GTTCTGGGCCGCACGGG 3′1465 and reverse 106R5′ 
GGCAAAGATTCGATGATT 3´88R The second PCR 
was carried out using one of two primer sets; in one 
instance, 2A ITS-1 primers were employed, whereas 
in the second instance 2B ITS-1 primers ( ITS1-ITS2, 
panfungal primers) were used. The second PCR was 
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carried out with 0.5 μl of the product obtained in the 
first PCR, and was amplified with 2A ITS-1 primers 
with 30 cycles of 45 s at 94°C, 1 min at 52°C, and 45 s at 
72°C. The oligonucleotides used were forward 17815′ 
GCGTCTA GACCTGCGGAAGGATCA 3´1798 and 
reverse 20R5′ GCGAAGCTT GATCCGTTGTTGAAA 
3´5R. These primers contained extra nucleotides to 
provide a cloning site for the amplified PCR product. 
As an alternative second PCR, 2B ITS1-ITS2 primers 
were used. The second PCR was carried out with 0.5 
μl of the product obtained in the first PCR and was 
amplified with 35 cycles of 45 s at 94°C, 1 min at 55°C, 
and 45 s at 72°C. The oligonucleotides used were 
forward 17715´ TCCGTAGGTGAACCTGCGG 3´1790 
and reverse 50R5´ GCTGCGTTCTTCATCGATGC 3´30R 
which are the commonly used ITS1 and ITS2 primers 
developed by [30]. Amplified products were analyzed 
by agarose gel electrophoresis and stained with eth-
idium bromide. We wish to indicate that these PCR 
assays can amplify the vast majority of fungal DNA, 
however some fungal species may not be detected 
because of the primers or the conditions employed. 
Moreover, different combinations of these primers 
may provide a better coverage of other species. 
Mass Spectrometry Analysis 
Initially, proteins from brain samples were sep-
arated by polyacrylamide gel electrophoresis (PAGE) 
under reducing conditions according to Laemmli, 
with a 12.5% separating gel and a 5% stacking gel. 
Protein staining was carried out with GelCode Blue 
Stain Reagent (Thermo Scientific). Separation of pro-
teins and gel excision were carried out essentially as 
previously described [19]. Twelve stained sections 
(about 0.5-0.8 cm) were excised from the gel, and 
proteins were in-gel digested with trypsin, after re-
duction and alkylation. This procedure was per-
formed after drying, gel bands were destained in ac-
etonitrile:water (ACN:H2O, 1:1) and were reduced 
and alkylated. Thus, disulfide bonds from cysteinyl 
residues were reduced with 10 mM DTT for 1 h at 
60ºC, and then thiol groups were alkylated with 55 
mM iodoacetamide for 1 h at room temperature in the 
dark. The proteins were then digested in situ with 
sequencing grade trypsin (Promega, Madison, WI). 
The gel pieces were shrunk by dehydration in ace-
tonitrile, which was then removed. The gel pieces 
were then dried in a vacuum centrifuge. Afterwards, 
the dried gel pieces were re-swollen in 50 mM am-
monium bicarbonate pH 8.8 with 12.5 ng/μl trypsin 
for 1 h in an ice-bath. The digestion buffer was re-
moved and gels were covered again with 50 mM 
NH4HCO3 and incubated at 37°C for 12 h. Digestion 
was stopped by the addition of 1% TFA. Whole su-
pernatants were dried down and then desalted on 
OMIX C18 Pipette tips (Agilent) for the mass spec-
trometry analysis. The peptide extracts were com-
bined into 3 pools of discontinuous bands, to reduce 
the analysis by LC-MS to 4 runs per sample. The de-
salted protein digest was dried, resuspended in 10 µl 
of 0.1% formic acid and analyzed by RP-LC-MS/MS 
in an Easy-nLC II system coupled to a 
LTQ-Orbitrap-Velos-Pro hybrid mass spectrometer 
(Thermo Scientific). Concentration of peptides 
(on-line) was carried out by reverse phase chroma-
tography using a 0.1 mm × 20 mm C18 RP precolumn 
(Thermo Scientific), and then separated using a 
0.075mm x 150 mm C18 RP column (Thermo Scien-
tific) operating at 0.3 μl/min. Elution of peptides was 
performed using two different gradients: a 120 or 
180-min gradient from 5 to 40% solvent B (Solvent A: 
0.1% formic acid in water, solvent B: 0.1% formic acid, 
80% acetonitrile in water). ESI ionization was done 
using a Nano-bore emitter Stainless Steel ID 30 μm 
(Proxeon) interface. The Orbitrap resolution was set at 
30,000. Peptides were detected in survey scans from 
400 to 1600 amu (1 μscan), followed by twenty data 
dependent MS/MS scans (Top 20), using an isolation 
width of 2 u (in mass-to-charge ratio units), normal-
ized collision energy of 35%, and dynamic exclusion 
applied during 30 second periods. 
Mass spectrometry data processing 
Processing of the MS data was carried out as 
previously described [19]. Briefly, peptide identifica-
tion from raw data was carried out using the 
SEQUEST algorithm (Proteome Discoverer 1.3, 
Thermo Scientific). Database searching was per-
formed against uniprot-homo fasta and uniprot-fungi 
fasta.  
Histological analysis 
 Brain sections (5 μm) were fixed in 10% buffered 
formalin for 24 h and then embedded in paraffin fol-
lowing standard protocols. For immunohistochemical 
analysis, paraffin was removed and the tissues were 
rehydrated and boiled for 2 min in citrate buffer. Af-
ter, samples were incubated 10 min with ammonium 
chloride. Subsequently, tissue sections were incubated 
10 min with PBS/Triton X-100 0.1% and further in-
cubated for 20 min with PBS/BSA 2%. Sections were 
then incubated overnight at 4oC with mouse mono-
clonal antibody raised against human α-tubulin at a 
1:50 dilution, or rabbit polyclonal antibody raised 
against proteins obtained from C. glabrata at a 1:500 
dilution. After this incubation, the sections were 
washed with PBS and incubated for 1 hour at 37ºC 
with donkey anti-mouse IgG secondary antibody 
conjugated to Alexa 555 (Invitrogen) for α-tubulin and 
donkey anti-rabbit IgG secondary antibody conju-
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gated to Alexa 555 or Alexa 488 (Invitrogen) at a 1:500 
dilution for anti-C. glabrata. Afterwards, tissue sec-
tions were stained with DAPI (Merck). Then, samples 
were treated with Autofluorescence Eliminator Rea-
gent (Merck). Finally, sections were observed using a 
LSM710 confocal laser scanning microscope combined 
with the upright microscope stand AxioImager.M2 
(Zeiss). The spectral system employed was Quasar + 2 
PMTs. Zeiss ZEN 2010 Program.  
Results  
Search of fungal infection in CSF from ALS 
patients. Presence of fungal antigens 
 A highly sensitive slot-blot assay to analyze the 
presence of fungi in blood serum or CSF has been 
developed using specific antibodies against fungal 
antigens [20, 28, 31]. Samples are blotted onto a ni-
trocellulose membrane and then incubated with the 
corresponding primary antibody at the indicated di-
lution. Subsequently, the membrane is incubated with 
a peroxidase-conjugated secondary antibody and the 
film obtained is scanned. We have previously estab-
lished the cut-off values to determine negative or 
positive results [31]. We first tested a number of an-
tibodies raised against total fungal cells or purified 
enolase from C. famata, or a β-tubulin peptide specific 
for fungi. CSF samples from five ALS patients and 
from three controls (see Supplementary Table SI) were 
tested. Figure 1 shows representative results obtained 
with anti-C. albicans and enolase antibodies. A posi-
tive control using yeast proteins and a negative con-
trol containing TBS were used. Certainly, CSF sam-
ples from ALS patients rendered a clear positive re-
sult. Densitometric quantification of this assay em-
ployed a panel of different antibodies is presented in 
Table I indicating the positive reactivity for fungal 
antigens in all five patients. As expected, values ob-
tained in control CSF samples for a range of fungi 
were rather low. In contrast, slot-blot values from CSF 
of ALS patients were generally considerably higher. 
For example, CSF from patient 1 exhibited high values 
with several antibodies employed, including anti-C. 
famata, C. albicans, C. glabrata, enolase and β-tubulin. 
Further, high values were obtained in most cases with 
the anti-C. albicans, enolase and β-tubulin antibodies. 
Not all the antibodies exhibited a similar behavior, 
since in some instances the differences found with a 
given antibody were more pronounced between ALS 
and control CSFs. This may indicate that the fungal 
antigens present in ALS CSF immunoreact much bet-
ter than other anti-fungal antibodies. For example, 
this is the case of values obtained with anti-C. albicans 
antibodies that rendered a median of 131.2 in ALS and 
11.3 in controls, with a P=0.18 and the odds ratio of 
8.0. Considering all the values of Table I, the results 
obtained are: P=0.01 and odds ratio=4.8. Overall, 
these results indicate that fungal antigens are present 
in CSF from ALS patients.  
 
 
Figure 1 - Analysis of C. albicans and enolase antigens in CSF by slot-blot. 
20 µl CSF samples were diluted with 180 µl TBS and were blotted onto a nitrocel-
lulose membrane, which was incubated with the rabbit antiserum against C. albicans or 
enolase or recombinant MBP-enolase (primary antibody) as indicated and afterwards 
incubated with a rabbit anti rat IgG (secondary antibody). Positive control: control + 
200 ng yeast protein or purified MBP-enolase. Negative control: control – corre-
sponds to TBS alone.  
 
Table I. Fungal antigens present in CSF from ALS patients immunoreacting with antibodies against different yeast species. 
Patients C.famata C.albicans C.glabrata C.parapsilosis Penicillium Enolase β tubulin pep-
tide 
Patient 1 88±2.7 164±6.6 118±4.7 42±2.9 56±3.9 183±5.5 280±8.4 
Patient 2 17±1.4 65±4.1 58±4.0 32±2.2 15±1.2 150±4.5 52±3.6 
Patient 3 2±0.2 180±7.2 14±1.1 5±0.4 129±5.2 130±3.9 144±5.8 
Patient 4 39±3.1 56±3.8 1±0.1 48±3.4 17±1.4 60±4.2 153±6.1 
Patient 5 58±4.1 191±7.6 7±0.6 13±1.0 20±1.6 78±3.6 55±3.8 
Mean value 40.8 131.2 39.6 28 47.4 120.2 136.8 
Control 1 26±2.1 13±0.9 15±1.2 55±4.4 4±0.3 79±3.9 10±0.7 
Control 2 9±0.7 20±1.5 88±2.8 30±2.4 59±4.1 79±3.9 81±3.2 
Control 3 1±0.1 1±0.2 5±0.4 3±0.2 1±0.1 ND 1±0.2 
Mean value 12.0 11.3 33.3 29.3 21.3 79 30.6 
The median of the densitometric values of three experiments and the standard deviation are indicated. 
ND : not done 
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PCR assay of DNA isolated from CSF 
 An additional sensitive method to assess fungal 
infection is PCR [32, 33]. This technique has the added 
advantage that, after amplification of variable internal 
transcribed spacer 1 (ITS1) present between the rRNA 
genes (see scheme Figure 2), followed by agarose 
electrophoresis, sequencing of the amplified products 
reveals the fungal species present. However, it must 
be considered that the bulk of the DNA obtained is 
from human origin and only a very small amount 
would be fungal. Due to the limited volume of CSF, 
DNA could not be obtained from one of the patient 
samples; nonetheless, DNA was obtained from four 
CSF samples and the ITS1 sequences were amplified 
by nested PCR. After the first PCR, the second ampli-
fication was carried out with two independent primer 
pairs, as detailed in materials and methods (see 
scheme, Figure 2). The first primer pair, 2A ITS1, has 
been previously employed successfully by us [19, 31]. 
The second primer pair, 2B ITS1, have been described 
as panfungal primers [34], although they do not com-
pletely hybridize with Malassezia spp. The use of dif-
ferent primers may serve to a better coverage of sev-
eral fungal species. Moreover, future studies in this 
regard may benefit from the use of a wider range of 
primers to perform PCR studies. Notably, several 
products were amplified using 2A ITS1 primers in 
DNA extracted from CSF of ALS patients (Figure 2). 
In contrast, no products were obtained in control CSF 
samples or in controls for DNA extraction or PCR 
amplification without DNA, indicating that these 
amplified products were not due to contamination 
during DNA extraction or PCR amplification. DNA 
sequencing of the amplified products revealed the 
fungal species listed in Figure 2. Of interest, 2A ITS1 
primers amplifed Malassezia spp. (Figure 2). More 
importantly, C. albicans was also detected in two pa-
tients (2 and 3). The use of the panfungal primers 2B 
ITS1 also revealed the presence of C. albicans DNA in 
these two patients. Additionally, Rhodotorula muci-
laginosa was detected in patients 1 and 4 using the 2B 
ITS1 primer pair, but Malassezia spp. was not ampli-
fied. The possibility that DNA from other fungal spe-
cies was present in lower amounts is not excluded by 
these results. Moreover, it is possible that fungal cells 
from some species, which are present in brain tissue, 
are not released to the CSF. Taken together, these re-
sults strongly suggest 
that DNA from sev-
eral fungi is present in 
CSF from ALS pa-
tients. 
 
Figure 2. PCR analysis of DNA 
obtained from CSF. A) Sche-
matic representation of fungal 
rRNA genes and the ITS1 se-
quence. Location of the primers 
employed for the PCR: primers 1 
employed in the first PCR; primers 
2A employed in the second PCR; 
primers 2B employed in the second 
PCR and previously described as 
panfungal primers. B) PCR was 
carried out as described from 
DNA samples obtained from CSF 
of ALS patients or controls. The 
primers employed were primers 1 
for the first round PCR and pri-
mers 2A for the second round. 
After PCR, the samples were 
separated on agarose gels and 
stained with ethidium bromide. 
DNA size markers are shown on 
the left. Fungal species detected 
after sequencing each product is 
shown on the right. C) The sam-
ples obtained after the first PCR 
(primers 1) were amplified using 
primers 2B. PCR products were 
separated on agarose gels, ex-
tracted and sequenced. Fungal 
species detected are depicted on 
the right. Control PCR: PCR 
without DNA. CE: Control of 
DNA extraction without CFS 
DNA. 1: external primers. 2A: 
internal primers. 2B: panfungal 
primers. 
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Visualization of fungal infection in brain by 
immunohistochemistry  
 Given the above results in CSF, we next exam-
ined sections from the frontal cortex by immuno-
histochemistry using polyclonal rabbit antibodies 
raised against C. glabrata. Two individual fields are 
depicted for each sample (Figure 3). No immunoflu-
orescence was found in the frontal cortex from three 
control individuals (Supplementary Figure S1). In 
contrast, several neurons were immunopositive for C. 
glabrata and stained intracellular punctate bodies in 
the cytoplasm in ALS brain sections (Figure 3). These 
bodies resemble the intracellular morphology of other 
fungi, as reported previously [35, 36]. This fungal 
material was not observed in all neurons, because 
some of them were devoid of it. A wider film of one 
control and one ALS patient is shown in Figure 4. In 
this case, double immunofluorescence with an-
ti-tubulin and anti-C. glabrata antibodies was carried 
out. The subcellular distribution of tubulin was simi-
lar to that reported for neurons in some neurodegen-
erative diseases [37, 38]. The control sample was de-
void of fungal bodies whereas they were clearly ob-
served in the ALS patient. Apart from the intracellular 
punctate fungal material some extracellular bodies 
were also apparent. The morphological appearance is 
similar to our recently described findings in neurons 
from patients diagnosed with AD and these fungal 
bodies were known as intramycosomes [21] or per-
haps we can name them more adequately, endomy-
cosomes. Both, ALS and AD share parallels, but it is 
possible that the fungal species that affect both types 
of patients are different, and the genetic background 
of these patients also differs. The most important 
conclusion from these results is that fungal bodies can 
be observed in neurons from brains of ALS patients. 
Obviously, these studies do not indicate the exact 
fungal species present in these samples. 
Fungal DNA in brain samples 
 To analyze the potential fungal species present 
in brain samples from ALS patients, DNA was ex-
tracted from different CNS regions as indicated in 
Figure 5, and nested PCR was carried out as described 
using primers 1 in the first round and primers 2A in 
the second round. Interestingly, several DNA prod-
ucts were amplified in the three ALS patients ana-
lyzed, whereas no amplification was found in control 
sample (Figure 3). DNA sequencing of the isolated 
products resulted in the identification of the species, 
depicted in the bottom of Figure 5. Notably, several 
species could be identified from one patient and these 
species varied according to the CNS region analyzed. 
Further, different fungal species were detected in pa-
tients, although some were present in all three ALS 
patients. Accordingly, Malassezia globosa was present 
in most of the samples tested, whereas Cryptococcus 
neoformans was only detected in one sample. In our 
opinion, the most striking finding was that C. albicans 
appeared in all three patients. This yeast was also 
present in the CSF of several ALS patients (Figure 2) 
and it is acknowledged that C. albicans can be highly 
pathogenic; this also applies to the presence of C. 
neoformans in one patient. Possibly, the existence of 
different fungal species may account for the differ-
ences in the severity and evolution of disease ob-
served between ALS patients. Results from the second 
PCR using panfungal primers (2B), revealed that, as 
before, different fungal species could be detected. 
Trychoderma viridae was evident in all samples, 
whereas Cryptococcus magnus appeared in the four 
samples of patient 6. Collectively, these findings show 
that fungal infection of the CNS in ALS patients can 
be detected by PCR analysis, and different fungal 
species can also be determined. However, we do not 
know if the species identified by PCR are exactly the 
ones observed by immunofluorescence. 
Proteomic analyses of brain samples  
 Determination of the proteome of CSF or CNS 
from patients with neurodegenerative disease may 
serve to identify biomarkers for diagnosis, prognosis 
and evolution of each particular disease [39-42]. To 
our knowledge, no attempts have been made to iden-
tify fungal proteins in samples from ALS patients. 
Therefore, frontal cortex proteins from three ALS pa-
tients were initially separated by polyacrylamide gel 
electrophoresis and stained with Coomassie blue 
(Supplementary Figure S2). After gel staining, each 
lane was cut in 12 slices and digested with trypsin. 
Peptide extracts from three non-consecutive slices 
were pooled and analyzed by mass spectrometry. 
Consequently, four samples were analyzed by MS 
from each patient. Each sample was analyzed twice; 
the first analysis was carried out with a 120 min gra-
dient and the second analysis with 180 min gradient, 
in order to obtain more peptides by increasing the 
gradient time. Each run was analyzed with the Pro-
teome Discoverer (PD) 1.3 software, allowing the 
search for human and fungal proteins (Uniprot). In 
this manner, we could compare the peptides that are 
common to both human and fungi, to better discrim-
inate which peptides were specific for fungi. Addi-
tionally, the peptides obtained from the 180 min gra-
dient were analyzed with the Peaks 6 software, using 
the tool called PEAKS PTM which identifies 
post-translational modifications and variations due to 
potential mutations compiled in the Unimod li-
brary,as well as custom PTMs [43]. Each peptide 
identified as fungal by PD 1.3 was subjected to further 
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scrutiny by: 1) confirmation of the identification qual-
ity by visual inspection of the spectra; 2) search of 
homology to homo sapiens peptides by BLAST 
(ExPASY BLAST) to assess the differences between 
the corresponding human and fungal peptides; 3) 
peaks 6 study of the sequences assigned for fungi and 
human.  
 
 
Figure 3. Immunohistochemistry analysis 
of brain sections from the frontal cortex 
of ALS patients. Brain sections (frontal 
cortex) from ALS patients 9, 10 and 11 were 
observed with a confocal laser scanning micro-
scope. Sections were obtained from fixed tissue 
and immunohistochemistry analyses were 
carried out. Sections were incubated with anti-C. 
glabrata antibodies (1:500 dilution), followed by 
incubation with secondary antibody donkey 
anti-rabbit IgG conjugated to Alexa 555 (1:500). 
Subsequently, sections were incubated with 
DAPI (1 μg/ml). The different panels in the figure 
are indicated. Scale bar: 10 μm. 
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Figure 4. Immunohistochemistry analysis of brain sections from the frontal cortex of an ALS patient and a control. Brain sections (frontal cortex) from ALS 
patient 11 and control 6 were observed with a confocal laser scanning microscope. Sections were obtained from fixed tissue and immunohistochemistry analyses were carried 
out. Double immunofluorescence assay using anti-tubulin and anti-C. glabrata antibodies was carried out as detailed in Materials and Methods. DAPI appears in blue and anti-C. 
glabrata is shown in green. Human tubulin appears in red. The different panels in the figure are indicated.  
 
Figure 5. PCR analysis of different brain regions from three ALS patients. PCR was carried out as described. A) PCR analysis of different brain regions and controls 
using primers 1 and 2a. Table shows fungal species detected. B) PCR analysis of different brain regions and controls using primers 1 and 2b. Table shows fungal species detected. 
Control PCR: PCR without DNA. CE: Control of DNA extraction without CFS DNA. 1: external primers. 2A: internal primers. 2B: panfungal primers. FC: Frontal cortex. C: 
Cerebellum. O: Occipital cortex. WM: White matter. GM: Grey matter. 
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 The human proteins common to the three pa-
tients that were not present in a control recently pub-
lished by our laboratory are listed in Supplementary 
Table SIII. These proteins can be grouped according to 
their cellular function (Figure 6). These proteins may 
constitute the basis for future ALS biomarkers. 
 Regarding the identification of fungal proteins, 
Table II summarizes the fungal peptides obtained in 
the four fractions A-D from the three ALS patients. 
Although many more peptides may be present, we 
only indicate in Table II the peptides that belong to 
fungi beyond any doubt. We are confident that the 
peptides corresponding to α- and β-tubulin are of 
fungal origin. The identification of tubulin by prote-
omic analyses is consistent with the fact that tubulin is 
an abundant cellular protein. Fungal peptides corre-
sponding to actin have similarities to their human 
counterparts and could not therefore be unequivo-
cally identified. Nevertheless, the important finding 
from proteomic analysis is that fungal tubulin is pre-
sent in brain samples from ALS patients, further 
supporting the notion that fungal infection exists in 
the CNS of ALS patients. 
 
 
Figure 6. Functional grouping of human proteins specifically present in the frontal cortex from ALS patients. Human proteins which are common in the three 
ALS patients that are not present in control brain grouped by: a) cellular component; b) molecular function; c) protein class. 
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Table II. Proteomic analysis of fungal peptides present in brain samples from ALS patients. 
Patients Total peptides fungi 
identified with PD 1.3 
Peptides fungi not present in 
human database  
Peptides fungi confirmed with peaks PTM 
and manual inspection 
Certain fungal peptides 
Patient 6     
Fraction A 159 27 0  
Fraction B 188 50 2 AVLDLEPGTMDNVR β-tubulin 
AVCMLSNTTAIAEAWSR. α-tubulin 
Fraction C 192 37 0  
Fraction D 103 15 0  
Patient 7     
Fraction A 212 48 0  
Fraction B 210 49 1 AVCMLSNTTAIAEAWSR. α-tubulin 
Fraction C 213 33 0  
Fraction D 170 27 0  
Patient 8     
Fraction A 266 68 0  
Fraction B 207 48 1 CVSMLSNTTAIAEAWSR. α-tubulin 
Fraction C 210 34 0  
Fraction D 187 31 0  
PD1.3: Proteome Discoverer 1.3 software  
 
Discussion 
 The involvement of microbial infections in neu-
rodegenerative diseases has been deliberated by sev-
eral laboratories [44-47]. However, these studies have 
focused on viral or bacterial infections and less atten-
tion has been given to the possibility that fungal in-
fections may be responsible for some of these diseases 
[48]. The notion that fungal infection may be involved 
in the etiology of multiple sclerosis (MS) and AD has 
been considered in several reports from our labora-
tory [19-21, 28, 31, 49]. This concept is consistent with 
a number of clinical symptoms and observations re-
ported for these diseases. Similar to neurodegenera-
tive disease, fungal infections are usually chronic and 
progressive if untreated. Neuroinflammation is also 
repeatedly observed in the majority of neurodegen-
erative diseases, including ALS, and the continuous 
presence of fungal pathogens in the CNS can provoke 
not only chronic inflammation, but also the sustained 
production of microbial products. Both inflammation 
and microbial products, or even intracellular fungal 
cells (endomycosomes), could lead to neuronal de-
generation and death. Additionally, fungal infection 
could also account for the generation of granules of 
misfolded or aberrantly-processed proteins. Granular 
type may depend on a number of variables: 1) the 
subset of neural cells affected; 2) the individual fungal 
species infecting the CNS and the route of this infec-
tion; 3) the genetic background of the patient and, 4) 
the state of the immune system and the lifestyle of 
each individual. Differences in any of these parame-
ters could give rise to different pathologies. Con-
versely, if some neurodegenerative diseases are 
caused by fungal infections, it is also logical that they 
will share several similarities [50-52]. Our previous 
reports have provided evidence for fungal infections 
in MS and AD patients. Strikingly, chitin-like poly-
saccharides have been found in brains from MS and 
AD patients [22, 23] and most probably as a conse-
quence there are elevated levels of chitinase in AD 
CSF [24]. However, these researchers did not suggest 
the existence of fungal infection. The present work 
provides the first description of fungal proteins and 
DNA both in CSF and CNS from ALS patients. Fur-
thermore, immunofluorescence analysis clearly 
demonstrated fungal infection within some neurons, 
whereas other neighboring cells were devoid of this 
material. These observations provide direct evidence 
for the concept that ALS patients suffer fungal infec-
tions in some neurons of the CNS and are in accord 
with proteomic and PCR results identifying several 
fungal species. The recent finding that CSF from ALS 
patients contains elevated levels of chitinase [26, 27] 
do also support the idea of fungal infection in these 
patients. 
 ALS is a heterogeneous disease in which the 
evolution and clinical symptoms vary widely between 
patients; consequently, the disease can progress rap-
idly in some patients, who die within one year from 
diagnosis, while other patients can survive several 
years after the onset of clinical symptoms. The pres-
ence of different fungal species in each patient may 
account for this behavior. A number of similarities 
have been observed between different neurodegener-
ative diseases, particularly between MS, AD and Par-
kinson’s disease, as well as between ALS and FTD [4, 
53-55]. Notably, some likenesses have also been re-
ported between AD and ALS, including tangles of 
hyperphosphorylated tau in some neural cells from 
ALS patients with or without cognitive impairment, 
although in the latter there is a more widely distrib-
uted tau pathology [18, 56]. The existence of fungal 
infections both in AD and ALS patients also provides 
an explanation for the similarities reported between 
these diseases. It is well established that individual 
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genetic background can determine the likelihood of 
fungal infections [57-59]. Also, the presence of partic-
ular mutations in different genes in ALS patients may 
dictate their predisposition for ALS. In familial ALS 
cases, the most represented gene mutations are in the 
SOD1 gene [3]. SOD, an antioxidant defense gene, is 
involved in the innate immune response to a number 
of pathogens including fungi [60, 61]. Therefore, it is 
perhaps not surprising that SOD1 mutations that may 
affect the immune response in ALS patients [62, 63] 
might confer a greater sensitivity to fungal infection.  
 An additional symptom shared by AD and ALS 
is the occurrence of neuroinflammation and infiltra-
tion of T-lymphocytes in some areas of the CNS or 
spinal cord [52, 64-68]. Also, modifications in the 
number of different subsets of circulating 
T-lymphocytes have been noted in both disorders 
[69-71], suggesting that there is a systemic alteration 
of the immune system in patients suffering from these 
diseases. Supporting the concept that neuroinflam-
mation plays a part in ALS pathology, the number of 
regulatory T-lymphocytes correlates inversely with 
disease progression [72]. Neuroinflammation and T 
cell infiltration may be consistent with microbial in-
fection [73].  In this regard, our present findings reveal 
fungal infection both in CSF and brain samples from 
patients with ALS. Strikingly, the immunofluores-
cence results are also consistent with the concept that 
some neural cells contain intracellular fungal material 
or endomycosomes. This low burden of infection, 
together with the fact that endomycosomes are very 
small (about 1 µm in diameter), provides an explana-
tion for the hitherto elusive detection of this type of 
infection in ALS. If disseminated mycoses are re-
sponsible for ALS, this might explain why the disease 
appears suddenly in patients. Also, differences in the 
severity and evolution of clinical symptoms might be 
rationalized by the different fungal species, or even 
combinations of these species. Another possibility 
should be that immune tolerance to fungal infection is 
lost in these patients and inflammation provokes in-
jury and clinical symptoms [74]. Our present obser-
vations not only open a new field for the investigation 
of ALS, but if they are correct, ALS patients would 
immediately benefit from antifungal therapies. In this 
sense, clinical trials should definitively clarify the 
potential participation of fungal infection in the pa-
thology of ALS.  
Supplementary Material  
Table SI, SII, SIII, and Fig.S1-S2.  
http://www.ijbs.com/v11p0546s1.pdf 
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